+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Clinical Gastroenterology and Hepatology 16(12): 1937-1946.E8

Trough concentrations of vedolizumab were found to correlate with clinical response in phase 3 studies of patients with ulcerative colitis (UC) or Crohn's disease (CD). Nevertheless, there are no solid data to support monitoring of vedolizumab trough concentrations in treated patients. We investigated the correlation between vedolizumab exposure and response in a real-world population and aimed to identify patient factors that affect exposure and response. We performed a retrospective cohort study of 179 consecutive patients (66 with UC and 113 with CD) who began vedolizumab therapy from September 1, 2015, through October 1, 2016, at University Hospitals Leuven, Belgium. Serum concentrations of vedolizumab were measured before all infusions up to week 30. Effectiveness endpoints included endoscopic healing (UC, Mayo endoscopic sub-score ≤1; CD, absence of ulcers), clinical response (physicians' global assessment), and biologic response or remission (based on level of C-reactive protein) and were assessed at week 14 (for patients with UC) and week 22 (for patients with CD). A stepwise forward addition-backward elimination modeling approach was performed to identify factors independently associated with vedolizumab exposure and response. Vedolizumab trough concentrations >30.0 μg/mL at week 2, >24.0 μg/mL at week 6, and >14.0 μg/mL during maintenance therapy associated with a higher probability of attaining the effectiveness endpoints for patients with UC or CD (P < .05). Higher body mass and more severe disease (based on high level of C-reactive protein and low level of albumin and/or hemoglobin) at the start of vedolizumab therapy associated with lower trough concentrations of vedolizumab over the 30-week period and a lower probability of achieving mucosal healing (P < .05). Mucosal healing was achieved in significantly more patients with UC than patients with CD, even though a diagnosis of UC was not an independent predictor of higher vedolizumab trough concentrations. In a retrospective study of 179 patients with CD or UC, we observed a correlation between vedolizumab exposure and response. These findings support monitoring of vedolizumab trough concentrations to predict patients' outcome.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 063602053

Download citation: RISBibTeXText

PMID: 29704680

DOI: 10.1016/j.cgh.2018.04.040

Related references

Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview. Bmc Medicine 17(1): 89, 2019

Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences 64(6): 1651-1659, 2019

Higher Trough Vedolizumab Concentrations During Maintenance Therapy are Associated With Corticosteroid-Free Remission in Inflammatory Bowel Disease. Journal of Crohn's and Colitis 13(8): 963-969, 2019

Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months. Clinical Gastroenterology and Hepatology 15(11): 1750-1757.E3, 2017

Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. European Journal of Gastroenterology and Hepatology 31(4): 478-485, 2019

The Value Of Real-World Evidence To Support Value-Based Decision-Making: Examples For Vedolizumab In Inflammatory Bowel Disease. Value in Health 20(9): A638-A639, 2017

Oc.12.5 Vedolizumab Trough Levels And Clinical Outcomes In Inflammatory Bowel Disease. Digestive and Liver Disease 50(2): e99-e100, 2018

Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 17(8): 1533-1540.E2, 2019

Mo1842 - Clinical Experience with Vedolizumab Trough Levels in Inflammatory Bowel Disease. Gastroenterology 154(6): S-821-S-822, 2018

Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. Journal of Crohn's and Colitis 13(1): 12-18, 2019

Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 2019:, 2019

Higher Vedolizumab Trough Levels Associated with Remission in Inflammatory Bowel Disease (IBD) During Maintenance Therapy. Gastroenterology 152(5): S384-S385, 2017

Mo1835 - Soluble Madcam-1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Inflammatory Bowel Diseases under Vedolizumab: A Proof of Concept. Gastroenterology 154(6): S-819, 2018

Dried blood samples can support monitoring of infliximab concentrations in patients with inflammatory bowel disease: A clinical validation. British Journal of Clinical Pharmacology 85(7): 1544-1551, 2019

Rapid Response to Vedolizumab Therapy in Biologic-Naive Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology 17(1): 130-138.E7, 2019